Body mass index and cardiorenal outcomes in the EMPEROR ‐Preserved trial: Principal findings and meta‐analysis with the DELIVER trial

ConclusionsEmpagliflozin treatment resulted in broadly consistent cardiac effects across the range of BMI in patients with HFpEF. SGLT2i treatment yields benefit in patients with HFpEF regardless of baseline BMI.

Source: European Journal of Heart Failure - April 1, 2024 Category: Cardiology Authors: Naveed Sattar, Javed Butler, Matthew M.Y. Lee, Josephine Harrington, Abhinav Sharma, Faiez Zannad, Gerasimos Filippatos, Subodh Verma, James L. Januzzi, Jo ão Pedro Ferreira, Stuart J. Pocock, Egon Pfarr, Anne P. Ofstad, Martina Brueckmann, Tags: Research Article Source Type: research